April 12, 2021
Bayer:Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed iNHL
Bayer announced results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant progression-free survival (PFS) benefit for…